John Hopkins Webinar on transplant recipients and vaccines
They said after first shot 17 out of 800+patients had only a minimal antibody reaction .Also being on mycophelonate reduces effect of vaccines.WHATS GOING ON ??????
Interested in more discussions like this? Go to the Transplants Support Group.
It’s posted, but you need a passcode to access it. https://transplantvaccine.org/study-results-and-webinars/
@athenalee Are you able to open this link?
https://jamanetwork.com/journals/jama/fullarticle/2777685
Yes. I’ve read it. And, I saw the webinar. Thanks.
Oh. I thought you meant you didn't have a pass code to access the article. :/
No. I’m sorry. You had asked about the recording....which I had found earlier, but didn’t post it since it required a passcode. And, I couldn’t find any reference as to how to get said passcode.🤔
@snorris, Thank you for the link to the interview. It is very helpful and has given me the information in clear understandable terms.
Welcome to Connect. I can see that you have ben a member for a while, and that this is your first post. I am glad that you chose to jump in with this information.
Are you a transplant recipient?
Got it! Thanks!
Hi Rosemary. My husband received his new liver at Mayo Rochester in October 2018. It’s been a long road, 33 days in hospital post transplant, he’s doing well now, and we have found this forum very helpful.
https://www.dovepress.com/coronavirus-disease-2019-covid-19-and-transplantation-pharmacotherapeu-peer-reviewed-fulltext-article-TCRM
This link is to a medical journal that deals with Covid 19. Transplants, and treatments.
Evidently Tacrolimus is a prophylactic for Covid 19 in preventing sever infection.
Tacrolimus is immunosuppressive by inhibiting calcineurin, and suppressing the early phase of T-cell activation, and the expression of many cytokines (IL-2, IL-4, TNF-α and IFN-γ) that are needed in the activation of the cellular immune response, possibly preventing a cytokine storm as observed in severe COVID-19.Jun 27, 2020
https://www.ncbi.nlm.nih.gov › pmc
Calcineurin inhibitors revisited: A new paradigm for COVID-19? - NCBI - NIH